NEW TREATMENTS FOR MYELODYSPLASTIC SYNDROMES
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; line-height: 200%; text-align: justify;"><span style="font-size: 12pt; line-height: 200%; font-family: " lang="EN-US">In the last decade, significant advances have been made in the tr...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2010-05-01
|
| Series: | Mediterranean Journal of Hematology and Infectious Diseases |
| Subjects: | |
| Online Access: | http://www.mjhid.org/article/view/6072 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850084582360088576 |
|---|---|
| author | Mariangela Greco Francesco D'Alò Marianna Criscuolo Maria Teresa Voso |
| author_facet | Mariangela Greco Francesco D'Alò Marianna Criscuolo Maria Teresa Voso |
| author_sort | Mariangela Greco |
| collection | DOAJ |
| description | <p class="MsoNormal" style="margin: 0cm 0cm 0pt; line-height: 200%; text-align: justify;"><span style="font-size: 12pt; line-height: 200%; font-family: " lang="EN-US">In the last decade, significant advances have been made in the treatment of patients with Myelodysplastic Syndromes (MDS).<span style="mso-spacerun: yes;"> </span>Although best supportive care continues to have an important role in the management of MDS, todate the therapeutic approach is diversified according to IPSS risk group, karyotype, patient’s age, comorbidities, and compliance. </span></p><p class="MsoNormal" style="margin: 0cm 0cm 0pt; line-height: 200%; text-align: justify;"><span style="font-size: 12pt; line-height: 200%; font-family: " lang="EN-US">Hematopoietic growth factors play a major role in lower risk MDS patients, and include high dose erithropoiesis stimulating agents, which were shown to prolong survival, and thrombopoietic receptor agonists. Standard supportive care should also include iron chelating therapy to reduce organ damage related to iron overload in transfusion-dependent patients. Biologic therapies have been introduced in MDS, with lenalidomide, which has been shown to induce transfusion independence in most patients with the 5q- Syndrome. <span style="mso-spacerun: yes;"> </span>Hypomethylating agents have shown efficacy in INT-2/high risk MDS patients, reducing the risk of leukemic transformation and increasing survival. Other agents under development for the treatment of MDS include histone deacetylase inhibitors, farnesyltransferase inhibitors, clofarabine and ezatiostat.</span></p> |
| format | Article |
| id | doaj-art-b0f61382a6c44635bf2bf5187d03b238 |
| institution | DOAJ |
| issn | 2035-3006 |
| language | English |
| publishDate | 2010-05-01 |
| publisher | PAGEPress Publications |
| record_format | Article |
| series | Mediterranean Journal of Hematology and Infectious Diseases |
| spelling | doaj-art-b0f61382a6c44635bf2bf5187d03b2382025-08-20T02:43:58ZengPAGEPress PublicationsMediterranean Journal of Hematology and Infectious Diseases2035-30062010-05-0122e2010021e2010021NEW TREATMENTS FOR MYELODYSPLASTIC SYNDROMESMariangela GrecoFrancesco D'AlòMarianna CriscuoloMaria Teresa Voso<p class="MsoNormal" style="margin: 0cm 0cm 0pt; line-height: 200%; text-align: justify;"><span style="font-size: 12pt; line-height: 200%; font-family: " lang="EN-US">In the last decade, significant advances have been made in the treatment of patients with Myelodysplastic Syndromes (MDS).<span style="mso-spacerun: yes;"> </span>Although best supportive care continues to have an important role in the management of MDS, todate the therapeutic approach is diversified according to IPSS risk group, karyotype, patient’s age, comorbidities, and compliance. </span></p><p class="MsoNormal" style="margin: 0cm 0cm 0pt; line-height: 200%; text-align: justify;"><span style="font-size: 12pt; line-height: 200%; font-family: " lang="EN-US">Hematopoietic growth factors play a major role in lower risk MDS patients, and include high dose erithropoiesis stimulating agents, which were shown to prolong survival, and thrombopoietic receptor agonists. Standard supportive care should also include iron chelating therapy to reduce organ damage related to iron overload in transfusion-dependent patients. Biologic therapies have been introduced in MDS, with lenalidomide, which has been shown to induce transfusion independence in most patients with the 5q- Syndrome. <span style="mso-spacerun: yes;"> </span>Hypomethylating agents have shown efficacy in INT-2/high risk MDS patients, reducing the risk of leukemic transformation and increasing survival. Other agents under development for the treatment of MDS include histone deacetylase inhibitors, farnesyltransferase inhibitors, clofarabine and ezatiostat.</span></p>http://www.mjhid.org/article/view/6072Myelodysplastic syndrome |
| spellingShingle | Mariangela Greco Francesco D'Alò Marianna Criscuolo Maria Teresa Voso NEW TREATMENTS FOR MYELODYSPLASTIC SYNDROMES Mediterranean Journal of Hematology and Infectious Diseases Myelodysplastic syndrome |
| title | NEW TREATMENTS FOR MYELODYSPLASTIC SYNDROMES |
| title_full | NEW TREATMENTS FOR MYELODYSPLASTIC SYNDROMES |
| title_fullStr | NEW TREATMENTS FOR MYELODYSPLASTIC SYNDROMES |
| title_full_unstemmed | NEW TREATMENTS FOR MYELODYSPLASTIC SYNDROMES |
| title_short | NEW TREATMENTS FOR MYELODYSPLASTIC SYNDROMES |
| title_sort | new treatments for myelodysplastic syndromes |
| topic | Myelodysplastic syndrome |
| url | http://www.mjhid.org/article/view/6072 |
| work_keys_str_mv | AT mariangelagreco newtreatmentsformyelodysplasticsyndromes AT francescodalo newtreatmentsformyelodysplasticsyndromes AT mariannacriscuolo newtreatmentsformyelodysplasticsyndromes AT mariateresavoso newtreatmentsformyelodysplasticsyndromes |